Novo Nordisk A/S $NVO is TrueMark Investments LLC’s 10th Largest Position

TrueMark Investments LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 20.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 193,853 shares of the company’s stock after buying an additional 33,437 shares during the quarter. Novo Nordisk A/S makes up approximately 1.9% of TrueMark Investments LLC’s portfolio, making the stock its 10th largest position. TrueMark Investments LLC’s holdings in Novo Nordisk A/S were worth $9,863,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in NVO. Martin Capital Partners LLC raised its stake in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after purchasing an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas boosted its position in shares of Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after buying an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC grew its holdings in shares of Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after buying an additional 37,453 shares in the last quarter. Markel Group Inc. grew its holdings in shares of Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Novo Nordisk A/S during the third quarter valued at $1,294,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $36.01 on Monday. The firm has a market cap of $160.78 billion, a price-to-earnings ratio of 10.38, a P/E/G ratio of 8.52 and a beta of 0.73. Novo Nordisk A/S has a 1 year low of $35.85 and a 1 year high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The business has a fifty day simple moving average of $45.92 and a 200 day simple moving average of $50.42.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 708.0%. Novo Nordisk A/S’s payout ratio is presently 52.74%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday. They issued a “peer perform” rating for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo’s insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a “peer perform” rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.